About Exagen Inc.
For more information, please visit Exagen.com and follow @ExagenInc on Twitter.
Investor Relations
rdouglas@exagen.com
760.560.1525
Company
kadawi@exagen.com
![](https://ml.globenewswire.com/media/ZDY2NjAxMmYtMmQ0Ny00MWU4LWIwOGQtZjcyMDQ0NmFlOTBjLTEwMjI1NDU=/tiny/Exagen-Inc-.png)
2023 GlobeNewswire, Inc., source
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.038 USD | -5.66% |
|
+9.90% | +2.72% |
May. 14 | Cantor Fitzgerald Adjusts Price Target on Exagen to $7 From $5, Maintains Overweight Rating | MT |
May. 13 | Exagen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
About Exagen Inc.
For more information, please visit Exagen.com and follow @ExagenInc on Twitter.
Investor Relations
rdouglas@exagen.com
760.560.1525
Company
kadawi@exagen.com
2023 GlobeNewswire, Inc., source
1st Jan change | Capi. | |
---|---|---|
+2.72% | 37.53M | |
+19.95% | 83.53B | |
-22.52% | 75.4B | |
+2.32% | 26.73B | |
-3.96% | 18.25B | |
+6.95% | 18.12B | |
+8.64% | 16.51B | |
+78.56% | 14.05B | |
+78.27% | 13.03B | |
-27.89% | 12.67B |